NCNA

NuCana

NCNA

Market cap $7.37M

Overview Fund Activity

3.86 USD

+0.19

5.18%

At close Updated Sep 12, 4:00 PM EDT

Pre-market

After hours

4.03

+0.17

4.4%

1 day

5.18%

5 days

34.03%

1 month

-18.05%

3 months

-87.3%

6 months

-97.62%

Year to date

-98.44%

1 year

-99.24%

5 years

-99.99%

10 years

-100%

About: NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.

Employees: 22

Healthcare Biotechnology

0

Funds holding %

of 7,462 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

75% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 4

30% more funds holding

Funds holding: 10 [Q1] → 13 (+3) [Q2]

0.06% more ownership

Funds ownership: 0% [Q1] → 0.06% (+0.06%) [Q2]

84% less capital invested

Capital invested by funds: $238K [Q1] → $38.8K (-$199K) [Q2]

See Fund Rankings

Financial journalist opinion

Based on 3 articles about NCNA published over the past 30 days

NuCana Compliant with All Nasdaq Continued Listing Criteria

EDINBURGH, United Kingdom, Sept. 05, 2025 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) (“NuCana” or the “Company”) announced that it has received formal notification from The Nasdaq Stock Market on September 4, 2025 confirming that the Company is in compliance with all applicable Nasdaq continued listing criteria, including the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2).

NuCana Compliant with All Nasdaq Continued Listing Criteria

NuCana to Present Data on NUC-7738's Synergy with PD-1 Inhibitors at the ESMO Congress 2025

EDINBURGH, United Kingdom, Sept. 03, 2025 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) (“NuCana” or the “Company”) announced a presentation at the upcoming annual European Society for Medical Oncology (“ESMO”) congress being held October 17-21, 2025 in Berlin, Germany (the “ESMO Congress 2025”).

NuCana to Present Data on NUC-7738's Synergy with PD-1 Inhibitors at the ESMO Congress 2025

NuCana Reports Second Quarter 2025 Financial Results and Provides Business Update

First Patients Dosed on Expansion Study of NUC-7738 in Combination with Pembrolizumab for Patients with PD-1 Inhibitor-Resistant Melanoma

NuCana Reports Second Quarter 2025 Financial Results and Provides Business Update

NuCana Announces ADS Ratio Change

EDINBURGH, United Kingdom, Aug. 01, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) announces that it will implement the Company's previously disclosed plans to change the ratio of its American Depository Shares (“ADSs”) to its ordinary shares from one (1) ADS, representing twenty-five (25) ordinary shares, to one (1) ADS representing five thousand (5,000) ordinary shares (the "ADS Ratio"). The change in the ADS Ratio is expected to become effective on August 11, 2025 (the "Effective Date").

NuCana Announces ADS Ratio Change

NuCana Cancels All Outstanding Series A Warrants Following Strategic ATM Execution

EDINBURGH, United Kingdom, July 21, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) announces it has successfully canceled all remaining Series A Warrants, issued in the registered direct offering on May 7, 2025, pursuant to its letter agreements with the holders of the Series A Warrants, having raised the full amount of capital required to complete the cancellation through its at-the-market offering.

NuCana Cancels All Outstanding Series A Warrants Following Strategic ATM Execution

NuCana Announces Plan to Implement ADS Ratio Change

EDINBURGH, United Kingdom, July 11, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) announced plans to change the ratio of its American Depository Shares (“ADSs”) to its ordinary shares from one (1) ADS, representing twenty-five (25) ordinary shares, to one (1) ADS representing five thousand (5,000) ordinary shares (the "ADS Ratio"). The change in the ADS Ratio is expected to become effective on or about August 8, 2025 (the "Effective Date").

NuCana Announces Plan to Implement ADS Ratio Change

NuCana Reports First Quarter 2025 Financial Results and Provides Business Update

Initiation of Expansion Study of NUC-7738 in Combination with Pembrolizumab for Patients with PD-1 Inhibitor-Resistant Melanoma

NuCana Reports First Quarter 2025 Financial Results and Provides Business Update

NuCana Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update

Remains on Track to Initiate an Expansion Study of NUC-7738 in Combination with Pembrolizumab for Patients with PD-1 Inhibitor-Resistant Melanoma in 2025

NuCana Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update

Aurion Biotech Appoints Donald Munoz as Chief Financial Officer

SEATTLE & CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--Aurion Biotech, Inc. (Aurion), whose mission is to restore vision to millions of patients with life-changing regenerative therapies, announced today that Donald Munoz is joining the Company as chief financial officer (CFO), reporting to Greg Kunst, chief executive officer (CEO). “We are delighted to welcome Don to our executive team,” said Greg Kunst, Aurion's CEO. “Don's track record of strategic and operational financial leadership, coupled.

Aurion Biotech Appoints Donald Munoz as Chief Financial Officer

NuCana Reports Third Quarter 2024 Financial Results and Provides Business Update

Presented Encouraging Phase 2 Data on NUC-7738 in Combination with Pembrolizumab at the European Society for Medical Oncology (ESMO) Congress 2024

NuCana Reports Third Quarter 2024 Financial Results and Provides Business Update

See News Rankings

Charts implemented using Lightweight Charts™